Gene-Editing breakthrough: CRISPR stem cell therapy targets sickle cell disease
Disease control
Recruiting now
This early-stage trial tests a one-time infusion of the patient's own blood stem cells, which have been corrected using CRISPR gene editing to fix the sickle cell mutation. The goal is to reduce painful blockages in blood vessels and other complications. Nine people aged 12 to 35…
Phase: PHASE1, PHASE2 • Sponsor: Mark Walters, MD • Aim: Disease control
Last updated May 11, 2026 05:10 UTC